Several compounds targeting FAK are under clinical and preclinical trials as specific deletion of FAK has been shown to reduce HCC proliferation and tumor-induced overexpression of cMET and β-catenin 47. This evidence concerns the gene PTK2 and hepatocellular carcinoma.